Eli Lilly and Co/ US5324571083 /
2024-07-12 9:59:45 PM | Chg. +14.30 | Volume | Bid2:00:00 AM | Ask12:39:53 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
948.55USD | +1.53% | 131,956 Turnover: 55.96 mill. |
-Bid Size: - | -Ask Size: - | 901.14 bill.USD | 0.49% | 162.96 |
GlobeNewswire
07-01
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studyi...
GlobeNewswire
06-28
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire
06-21
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
GlobeNewswire
06-11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
06-10
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifen...
GlobeNewswire
06-06
Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Laso...
GlobeNewswire
05-30
Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024
GlobeNewswire
05-30
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
05-24
Gov. Holcomb Joins Lilly to Announce Additional $5.3 Billion Investment at LEAP District
GlobeNewswire
05-16
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED ...
GlobeNewswire
05-16
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
GlobeNewswire
05-13
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update